The U.S. Food and Drug Administration states that gray-market GLP-1 drugs obtained outside the legal drug supply chain are not evaluated for safety, quality, or efficacy and may be counterfeit, contaminated, or improperly compounded.
high
regulatory
Regulatory agencies advise that products outside approved distribution and manufacturing controls carry increased safety risks.